Vision 1 year after gene therapy for Leber's congenital amaurosis - Test2 - elhamkhani - TriplyDB

Vision 1 year after gene therapy for Leber's congenital amaurosis

Vision 1 year after gene therapy for Leber's congenital amaurosis

http://www.wikidata.org/entity/Q24607981

about

Gene therapy rescues cone function in congenital achromatopsia.Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration Clinical Trials in Retinal Dystrophies Cloning humans? Biological, ethical, and social considerations Regenerative medicine for the special senses: restoring the inputs.Current prospects and challenges for epilepsy gene therapy Gene therapy of inherited retinal degenerations: prospects and challenges AAV-mediated gene therapy in mouse models of recessive retinal degeneration Immunology of AAV-Mediated Gene Transfer in the Eye A comprehensive review of retinal gene therapy Gene Augmentation Therapy Restores Retinal Function and Visual Behavior in a Sheep Model of CNGA3 Achromatopsia MicroRNA-restricted transgene expression in the retina What Is Next for Retinal Gene Therapy?Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.AAV-mediated cone rescue in a naturally occurring mouse model of CNGA3-achromatopsia Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial.Passive immunization against HIV/AIDS by antibody gene transfer.A flow cytometric approach to study the mechanism of gene delivery to cells by gemini-lipid nanoparticles: an implication for cell membrane nanoporation Macular function in macular degenerations: repeatability of microperimetry as a potential outcome measure for ABCA4-associated retinopathy trials.Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years.Maintaining ocular safety with light exposure, focusing on devices for optogenetic stimulation.Functional and behavioral restoration of vision by gene therapy in the guanylate cyclase-1 (GC1) knockout mouse.GFAP-driven GFP expression in activated mouse Müller glial cells aligning retinal blood vessels following intravitreal injection of AAV2/6 vectors Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb.Self-complementary AAV5 vector facilitates quicker transgene expression in photoreceptor and retinal pigment epithelial cells of normal mouse.Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy Gene therapy in ophthalmology.Gene augmentation for adRP mutations in RHO.Viral and nonviral delivery systems for gene delivery Expression of wild-type Rp1 protein in Rp1 knock-in mice rescues the retinal degeneration phenotype Self-complementary AAV-mediated gene therapy restores cone function and prevents cone degeneration in two models of Rpe65 deficiency.Blue cone monochromacy: visual function and efficacy outcome measures for clinical trials.Bestrophin 1 and retinal disease.Vector platforms for gene therapy of inherited retinopathies.Recombinant vectors based on porcine adeno-associated viral serotypes transduce the murine and pig retina Temporal interactions during paired-electrode stimulation in two retinal prosthesis subjects.Gene therapy rescues cone structure and function in the 3-month-old rd12 mouse: a model for midcourse RPE65 leber congenital amaurosis Altered expression of retinal molecular markers in the canine RPE65 model of Leber congenital amaurosis Assessment of tropism and effectiveness of new primate-derived hybrid recombinant AAV serotypes in the mouse and primate retina

P2860

Q24595787-ECF329D3-D9AE-41F6-AE6A-39850E04ED51 Q24627838-458BCA34-CD03-4554-BEBC-FDF75D4E3110 Q26767086-89864551-D75D-4751-95C5-D579D7B84934 Q26801506-5CF3D77A-44EF-4932-94B7-0207FBEBDB65 Q27000739-D1ABDA56-D2A6-4A37-9B0D-250DA983FB10 Q27002627-94CBACB9-1030-4262-A246-7F988A7FFEC4 Q27009261-A20CAF4F-A7BF-4100-9386-BFC9DE480B96 Q27009291-E310412F-E48C-4074-9FC2-F5A52191DA4E Q27023474-5F533C96-9CAC-4EDA-9859-CE284A4072EC Q27023914-E4C16E5E-E076-42D5-8C86-86DA289ABF8A Q27318262-A268E945-A1D3-4A54-99CB-CB021F863DAE Q27332143-7A69A0DE-9053-409F-9CF4-CC93A606710E Q28082800-45694D1D-FEF6-4718-9F7D-4A2A05D6D8DD Q28262431-FE501346-771B-4EDE-B64D-44508181ACAD Q28306059-81B02415-249F-4E40-AC53-E33665656359 Q28730645-7B2480A6-32E9-4F87-9233-F8946CD6EF58 Q30277652-508C9C93-6BF8-4683-8503-165239B84613 Q30358434-9C3F389E-4909-4C48-85FC-387D8D9FBD96 Q30402212-FBBCB8A2-ECBF-4BFF-BA4A-83949A0CF391 Q30512453-DAC2E536-6F33-4770-A656-D3E262EF4864 Q30537764-E33719AE-85DB-4F99-8BA8-38208B71D143 Q30734491-F47524B4-2B56-448A-93E5-B9100DFD5172 Q33622429-679A7A2F-D7F8-46B4-9B3F-C4BB3D52B79B Q33680151-D2A3580D-6845-42DB-B220-5B90D74FA66F Q33730469-8D71BC1D-08DB-4D57-BCFE-F1309F9C3499 Q33787600-D474F140-A318-4F44-AA7C-4C0DF1D664E5 Q33992484-4F9F0767-17B2-444A-AD55-9771FE7620D5 Q33993709-BA33B556-BAD9-450A-828F-99D234B519F5 Q34083185-212717E8-B5FE-48CB-B4AE-1A15CCE9B7C3 Q34315475-6241D944-D274-492C-AD6F-2D448B7BA6D4 Q34395630-D4182C3D-834D-454D-8E91-73E4600C6919 Q34461299-F781C07D-1C12-4B31-A6FB-6AB7A162E24B Q34473512-180C4320-72F9-4A07-A273-271F70439ABF Q34550522-C86E92F4-CD62-4872-9634-DE0FE7F91179 Q34561531-70C40722-0EF5-4624-A26C-ED9535C4E8AC Q34631983-3A9258B4-1FA7-4D8A-9B4C-69FF83A1BE5C Q34646819-4AC91EB6-B391-42F0-9DC1-B2B77227E105 Q34646896-34E7FDEA-631F-4F83-AAFB-915A624C0311 Q34662339-9C99894F-13CC-4253-88FE-A1C6512BC94A Q34673011-AEF1C451-BE86-4C3A-984E-A838B064911D

P2860

Vision 1 year after gene therapy for Leber's congenital amaurosis

http://www.wikidata.org/entity/Q24607981

description

2009 nî lūn-bûn

@nan

2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Vision 1 year after gene therapy for Leber's congenital amaurosis

@ast

Vision 1 year after gene therapy for Leber's congenital amaurosis

@en

Vision 1 year after gene therapy for Leber's congenital amaurosis

@nl

type

label

Vision 1 year after gene therapy for Leber's congenital amaurosis

@ast

Vision 1 year after gene therapy for Leber's congenital amaurosis

@en

Vision 1 year after gene therapy for Leber's congenital amaurosis

@nl

prefLabel

Vision 1 year after gene therapy for Leber's congenital amaurosis

@ast

Vision 1 year after gene therapy for Leber's congenital amaurosis

@en

Vision 1 year after gene therapy for Leber's congenital amaurosis

@nl

P1433

Q24607981-94048C39-06EA-41F8-B906-C801514994DE

P1476

Q24607981-D659E236-08D0-4F22-9AAC-401471AE50A1

P2093

Q24607981-01620648-8FB2-4BBF-8112-C0A21B25B691

Q24607981-051EB161-3BE2-44DB-B5F0-CD5803CD6FA4

Q24607981-131F01F4-EA1F-44DB-B4C5-EDE97FCDD3C0

Q24607981-18987B8E-5D46-447B-B17A-C90EB14E19FF

Q24607981-2BFBCA9C-5F26-40BF-B8BD-1A3E1CEA98BC

Q24607981-53F66225-85AB-4252-BBC0-5470E8045415

Q24607981-99F5F3E0-2427-4A1E-8A01-AE8AF78EEA94

Q24607981-A0FC9E7E-DA1F-424A-B2C7-98E4E397A485

Q24607981-A8F54FC3-92CE-43C1-AE15-D93EB3E6F96C

Q24607981-C4DBBE9E-C250-4F28-851C-7B8B16F4C177

P2860

Q24607981-2F799C28-9F34-43F2-A508-B1647206F500

Q24607981-50217519-E1A0-4998-82F0-F26C70498A9A

Q24607981-6813E1FD-FBCC-4126-9C10-67EC380B1653

Q24607981-BE9A9143-159A-4803-A89C-E8F2F834FCF7

Q24607981-D1E62E0B-B7B0-4C13-A93F-306956BE0B33

P304

Q24607981-491A08AA-8397-4423-88D3-F46FC6736D4B

P31

Q24607981-A1A6567D-FD94-41DB-BD63-92CBE54DE6C9

P3181

Q24607981-DDCD5DB2-E0AA-4728-BB9C-465F4DFBF366

P356

Q24607981-CFFBE99B-6263-4E0F-AD29-1CF35202ACB3

P407

Q24607981-4B0F7ABE-745C-4A73-B067-32DBDE32E4FE

P433

Q24607981-106471B4-C2DB-4FFC-B583-1776BC019421

P478

Q24607981-9DB6FED8-2EF9-4B83-8733-8A474AB65988

P577

Q24607981-6458530F-8F43-4636-895B-E3C3CFB19597

P698

Q24607981-48324624-a7a9-4b99-a348-60dea04c648f

Q24607981-B0AC8E1B-6DD0-4083-A2D8-CA867FA8009B

P921

Q24607981-6E59DBAA-EE1B-4ED8-B56A-544FB492F0C6

Q24607981-F7CE658B-0075-492E-AF87-FA1246656F29

P932

Q24607981-38908028-A3D1-4DAE-B307-421AA93C5DFB

P3181

P356

P1433

The New England Journal of Medicine

P1476

Vision 1 year after gene therapy for Leber's congenital amaurosis

@en

P2093

Alejandro J Roman

http://www.w3.org/2001/XMLSchema#string

Alexander Sumaroka

http://www.w3.org/2001/XMLSchema#string

Artur V Cideciyan

http://www.w3.org/2001/XMLSchema#string

Barry J Byrne

http://www.w3.org/2001/XMLSchema#string

Elizabeth A M Windsor

http://www.w3.org/2001/XMLSchema#string

Samuel G Jacobson

http://www.w3.org/2001/XMLSchema#string

Sanford L Boye

http://www.w3.org/2001/XMLSchema#string

Shalesh Kaushal

http://www.w3.org/2001/XMLSchema#string

Sharon B Schwartz

http://www.w3.org/2001/XMLSchema#string

Thomas J Conlon

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial

Safety and efficacy of gene transfer for Leber's congenital amaurosis

Effect of gene therapy on visual function in Leber's congenital amaurosis

Leber congenital amaurosis: genes, proteins and disease mechanisms.

Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics.

P304

725-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4496487

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMC0903652

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

361

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19675341

http://www.w3.org/2001/XMLSchema#string

P921

P932

2847775

http://www.w3.org/2001/XMLSchema#string